The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) has plunged by -6.72 when compared to previous closing price of 0.68, but the company has seen a -8.06% decline in its stock price over the last five trading sessions. Accesswire reported 2023-09-06 that NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.
Is It Worth Investing in Petros Pharmaceuticals Inc (NASDAQ: PTPI) Right Now?
The 36-month beta value for PTPI is at 2.43. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTPI is 4.14M, and currently, shorts hold a 3.53% of that float. The average trading volume for PTPI on April 25, 2024 was 969.31K shares.
PTPI’s Market Performance
PTPI’s stock has seen a -8.06% decrease for the week, with a -59.59% drop in the past month and a -44.83% fall in the past quarter. The volatility ratio for the week is 9.35%, and the volatility levels for the past 30 days are at 11.14% for Petros Pharmaceuticals Inc The simple moving average for the past 20 days is -33.60% for PTPI’s stock, with a -64.33% simple moving average for the past 200 days.
PTPI Trading at -51.66% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.01% of loss for the given period.
Volatility was left at 11.14%, however, over the last 30 days, the volatility rate increased by 9.35%, as shares sank -59.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.69% lower at present.
During the last 5 trading sessions, PTPI fell by -8.06%, which changed the moving average for the period of 200-days by -66.07% in comparison to the 20-day moving average, which settled at $0.9096. In addition, Petros Pharmaceuticals Inc saw -55.01% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -2.34 for the present operating margin
- 0.72 for the gross margin
The net margin for Petros Pharmaceuticals Inc stands at -38.85. The total capital return value is set at -0.59. Equity return is now at value -91.54, with -33.16 for asset returns.
Based on Petros Pharmaceuticals Inc (PTPI), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 0.66. The interest coverage ratio of the stock is -49.8.
Currently, EBITDA for the company is -7.35 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of -0.12. The receivables turnover for the company is 2.62for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
In conclusion, Petros Pharmaceuticals Inc (PTPI) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
